Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center

Arthritis and Rheumatism

Volumn 64, Issue 11, 2012, Pages 3770-3778

  Cartin Ceba, Rodrigo ^a   Golbin, Jason M ^a,b   Keogh, Karina A ^a   Peikert, Tobias ^a   Sánchez Menéndez, Marta ^c   Ytterberg, Steven R ^a   Fervenza, Fernando C ^a   Specks, Ulrich ^a  

^a MAYO CLINIC   (United States)

^b Long Island Lung Center   (United States)

^c Centro Medico de Asturias   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; METHYLPREDNISOLONE; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BRONCHITIS; CELLULITIS; CHEST TIGHTNESS; CHILL; CLINICAL ASSESSMENT; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FEMALE; FEVER; HERPES ZOSTER; HORMONE SUBSTITUTION; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERTENSION; HYPOPITUITARISM; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RISK; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; REMISSION; THROAT TIGHTNESS; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEGENER GRANULOMATOSIS; WHEEZING;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 84868012506     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34584     Document Type: Article

References (39)

1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
2. Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et al, for the WGET Research Group. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007; 120: 643.e9-14.
3. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
4. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
5. The Wegener 's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.
6. Stevenson HC, Fauci AS,. Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B cell activation. Immunology 1980; 39: 391-7.
7. Cupps TR, Edgar LC, Fauci AS,. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128: 2453-7.
8. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW,. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103: 885-94.
9. Specks U, Fervenza FC, McDonald TJ, Hogan MC,. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836-40.
10. Keogh KA, Wylam ME, Stone JH, Specks U,. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-8.
11. Eriksson P,. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257: 540-8.
12. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U,. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-7.
13. Smith KG, Jones RB, Burns SM, Jayne DR,. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-82.
14. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D,. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45: 1432-6.
15. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-68.
16. Rhee EP, Laliberte KA, Niles JL,. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5: 1394-400.
17. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
18. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-20.
19. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
20. Jayne DR, Rasmussen N,. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72: 737-47.
21. Schmitt WH, Birck R, Heinzel PA, Gobel U, Choi M, Warnatz K, et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005; 20: 1083-92.
22. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ,. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65: 1440-8.
23. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al, for the International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001; 44: 912-20.
24. Russell KA, Wiegert E, Schroeder DR, Homburger HA, Specks U,. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103: 196-203.
25. Nifli AP, Notas G, Mamoulaki M, Niniraki M, Ampartzaki V, Theodoropoulos PA, et al. Comparison of a multiplex, bead-based fluorescent assay and immunofluorescence methods for the detection of ANA and ANCA autoantibodies in human serum. J Immunol Methods 2006; 311: 189-97.
26. Silva F, Specks U, Kalra S, Hogan MC, Leung N, Sethi S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement-a prospective, open-label pilot trial. Clin J Am Soc Nephrol 2010; 5: 445-53.
27. Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St Clair EW, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147: 611-9.
28. Ferraro AJ, Smith SW, Neil D, Savage CO,. Relapsed Wegener's granulomatosis after rituximab therapy-B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood. Nephrol Dial Transplant 2008; 23: 3030-2.
29. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-26.
30. Mantovani A, Luini W, Caniani GP, Speafico F,. Effect of chemotherapeutic agents on natural and BCG-stimulated macrophage cytotoxicity in mice. Int J Immunopharmacol 1980; 2: 333-9.
31. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
32. Hugle B, Solomon M, Harvey E, James A, Wadhwa A, Amin R, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken) 2010; 62: 1661-4.
33. Lund FE, Garvy BA, Randall TD, Harris DP,. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005; 8: 25-54.
34. Thomas CF Jr, Limper AH,. Pneumocystis pneumonia. N Engl J Med 2004; 350: 2487-98.
35. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA,. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006; 176: 6147-54.
36. Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA,. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody. J Immunol 2003; 171: 1423-30.
37. Marcotte H, Levesque D, Delanay K, Bourgeault A, de la Durantaye R, Brochu S, et al. Pneumocystis carinii infection in transgenic B cell-deficient mice. J Infect Dis 1996; 173: 1034-7.
38. Dunleavy K, Tay K, Wilson WH,. Rituximab-associated neutropenia. Semin Hematol 2010; 47: 180-6.
39. Furst DE,. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 2009; 39: 18-29.